Active Ingredient(s): Eptinezumab-jjmr
FDA Approved: * February 21, 2020
Pharm Company: * Lundbeck Seattle BioPharmaceuticals, Inc.
Category: Migraine / Tension Headache

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults.[3] It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta.[3][4][5] It is administered by intravenous infusion.[3] Eptinezumab was approved for medical use in the United States in February 2020.[6][7] Contents 1 History 2 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vyepti 100 mg/ml Intravenous Injection
NDC: 67386-130
Lundbeck Pharmaceuticals LLC